Hsbc Holdings PLC boosted its stake in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 7.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 638,529 shares of the exchange traded fund’s stock after purchasing an additional 46,339 shares during the quarter. Hsbc Holdings PLC’s holdings in SPDR S&P Biotech ETF were worth $78,049,000 at the end of the most recent quarter.
A number of other hedge funds have also recently bought and sold shares of XBI. SHP Wealth Management acquired a new position in shares of SPDR S&P Biotech ETF during the fourth quarter valued at about $31,000. DGS Capital Management LLC acquired a new stake in SPDR S&P Biotech ETF during the fourth quarter worth about $221,000. Blue Capital Inc. acquired a new stake in SPDR S&P Biotech ETF during the fourth quarter worth about $478,000. Compound Planning Inc. acquired a new stake in SPDR S&P Biotech ETF during the fourth quarter worth about $1,319,000. Finally, Connective Capital Management LLC bought a new position in SPDR S&P Biotech ETF during the fourth quarter valued at about $977,000.
SPDR S&P Biotech ETF Stock Up 3.7%
SPDR S&P Biotech ETF stock opened at $145.86 on Tuesday. The business has a 50 day moving average price of $133.84 and a two-hundred day moving average price of $127.95. The stock has a market cap of $9.31 billion, a price-to-earnings ratio of 11.47 and a beta of 0.85. SPDR S&P Biotech ETF has a 12 month low of $80.90 and a 12 month high of $146.77.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Biotech Index is a modified equal weight index.
Featured Articles
- Five stocks we like better than SPDR S&P Biotech ETF
- Buy CrowdStrike Before the Stock Split? Here’s the Case
- Investors Are Buying Into Sweetgreen Again—Should They?
- Burlington Is Winning Over Shoppers But Investors Need Patience
- USA Today’s Digital Revival Is Gaining Steam, But With Plenty of Risk
Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report).
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.
